5.Effects of TanshinoneⅡA Sulfonic Acid Sodium on Blood Supply and Hemorheology of Patients with Central Retinal Vein Occlusion
Hui WANG ; Xiao LI ; Yinqian HUANG
China Pharmacy 2015;26(35):5002-5004
OBJECTIVE:To observe the effects of Tanshinone ⅡA sulfonic acid sodium injection on blood supply and blood rheology of patients with central retinal vein occlusion )CRVO). METHODS:92 CRVO patients were selected and randomly divided into control group and trial group with 46 cases in each group. Control group was given routine treatment of laser photocoagulation;trial group was additionally given Tanshinone ⅡA sulfonic acid sodium injection 80 mg added into 0.9% Sodium chloride injection 150 ml,ivgtt,qd. A treatment course of 2 groups lasted for 7 days,and both received 4 courses of treatment. The hemodynamics and hemorheology of central retinal artery (CRA) were recorded in 2 groups before and after treatment. The fluorescence angiogra-phy (FFA) and optical coherence tomography (OCT) of 2 groups were also observed. RESULTS:Before treatment,there was no statistically significant difference in Vmax,Vmin and RI of CRA between 2 groups (P>0.05);after treatment,Vmax,Vmin and RI of CRA in 2 groups were improved significantly,the trial group was better than control group,with statistical significance(P<0.05). After treatment,whole blood high shear viscosity,whole blood low shear viscosity,plasma specific viscosity and fibrinogen of trial group were significantly lower than those of control group,and FFA and OCT of trial group were better than those of control group, with statistical significance(P<0.05). CONCLUSIONS:TanshinoneⅡA sulfonic acid sodium injection can obviously improve hemo-dynamics and hemorheology of CRVO and blood supply and vision of lateral eye.
6.Effect of refractive correction on the dynamic variation of diopter in children with hyperopia ametropic amblyopia
Cuie HUANG ; Hui ZHONG ; Changcheng XIAO
Chinese Journal of Primary Medicine and Pharmacy 2005;0(11):-
Objective To evaluate the effect of refractive correction on the dynamic variation of diopter in children with hyperopia ametropic amblyopia. Methods Optometry with 1 % atropine oculentum was used to examine 105 patients(210 eyes) with ametropic amblyopia aged 3~6 years old. The diopter of all the cases was compound hyperopic astigmatism. The prescriptions of spectacles were made according to that the diopter of retinoscopy subtracted different degree hyperopia. Thus,all the patients were divided into group 1(subtract 20% off the diopter of retinoscopy,30 cases),group 2(subtract 25% off the diopter of retinoscopy,40 cases),group 3(subtract 30% off the diopter of retinoscopy,35 cases). During three years' treating periods, their dynamic variation of hyperopia diopter were observed time yearly. Results The hyperopia diopter of each group reduced year after year. But the average reduction of hyperopia diopter of group was significantly lower than that of other two groups(P0.05).Conclusion Refractive corrections of different degree have effect on emmetropization of children with hyperopia ametropic amblyopia. Moderate undercorrection is useful on emmetropization of children with hyperopic ametropic amblyopia.
8.Selection of bFGF Mimic Peptide by Phage Display
Hui-Xian HUANG ; Xiao-Ping WU ; Shao-Hui CAI ; Xiao-Kun LI ;
China Biotechnology 2006;0(05):-
Objective: To obtain the bFGF mimic peptide binding to FGFR via phage display, and to provide the base for developing peptide agonist of bFGF. Methods: Using Balb/c 3T3 cells as the target cells and COS-7 cells as the subtractive panning, the phage display heptapeptide library was biopanned for 4 rounds to obtain the single phage clones. The affinity and the specificity of the clones were assessed by ELISA. DNA sequencing was applied to further analyze the positive clones. Results: Twelve positive clones were selected from the enriched phages. A group of hydrophobic peptides containing a conserved motif, PR, was identified. Conclusion: Two bFGF mimic heptapeptides binding to FGFR were selected, which may be used as the candidates for bFGF agonist.